Brokerages Anticipate Yumanity Therapeutics, Inc. (NASDAQ:YMTX) to Announce -$1.02 EPS

Brokerages expect that Yumanity Therapeutics, Inc. (NASDAQ:YMTXGet Rating) will announce ($1.02) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Yumanity Therapeutics’ earnings. The highest EPS estimate is ($0.95) and the lowest is ($1.09). Yumanity Therapeutics posted earnings per share of ($0.85) in the same quarter last year, which would indicate a negative year over year growth rate of 20%. The company is expected to report its next earnings report on Monday, January 1st.

On average, analysts expect that Yumanity Therapeutics will report full year earnings of ($4.42) per share for the current fiscal year, with EPS estimates ranging from ($5.00) to ($4.09). For the next fiscal year, analysts anticipate that the company will post earnings of ($6.16) per share, with EPS estimates ranging from ($7.35) to ($4.97). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Yumanity Therapeutics.

Yumanity Therapeutics (NASDAQ:YMTXGet Rating) last issued its earnings results on Thursday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.00). Yumanity Therapeutics had a negative return on equity of 108.22% and a negative net margin of 491.15%. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $1.81 million.

Separately, Zacks Investment Research raised Yumanity Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Thursday, March 31st.

Shares of YMTX opened at $1.15 on Wednesday. Yumanity Therapeutics has a 1 year low of $0.95 and a 1 year high of $16.89. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.31. The stock has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $2.83. The stock has a market cap of $12.47 million, a PE ratio of -0.30 and a beta of 0.88.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley bought a new stake in Yumanity Therapeutics during the 2nd quarter worth approximately $29,000. Virtu Financial LLC bought a new stake in Yumanity Therapeutics during the 4th quarter worth approximately $48,000. Bank of America Corp DE grew its position in Yumanity Therapeutics by 88,425.0% during the 2nd quarter. Bank of America Corp DE now owns 7,082 shares of the company’s stock worth $83,000 after acquiring an additional 7,074 shares during the last quarter. Jump Financial LLC bought a new stake in Yumanity Therapeutics during the 3rd quarter worth approximately $106,000. Finally, Geode Capital Management LLC grew its position in Yumanity Therapeutics by 29.2% during the 4th quarter. Geode Capital Management LLC now owns 49,888 shares of the company’s stock worth $147,000 after acquiring an additional 11,275 shares during the last quarter. Institutional investors and hedge funds own 27.71% of the company’s stock.

Yumanity Therapeutics Company Profile (Get Rating)

Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.

Featured Stories

Get a free copy of the Zacks research report on Yumanity Therapeutics (YMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.